These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26531700)

  • 21. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
    Minagar A; Ma W; Zhang X; Wang X; Zhang K; Alexander JS; Gonzalez-Toledo E; Albitar M
    Neurol Res; 2012 Jul; 34(6):611-8. PubMed ID: 22709658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T
    Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
    Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
    Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
    Røsjø E; Myhr KM; Løken-Amsrud KI; Bakke SJ; Beiske AG; Bjerve KS; Hovdal H; Lilleås F; Midgard R; Pedersen T; Šaltytė Benth J; Torkildsen Ø; Wergeland S; Michelsen AE; Aukrust P; Ueland T; Holmøy T
    J Neuroimmunol; 2015 Mar; 280():21-8. PubMed ID: 25773151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
    Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
    Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.
    Rudick RA; Lee JC; Cutter GR; Miller DM; Bourdette D; Weinstock-Guttman B; Hyde R; Zhang H; You X
    Arch Neurol; 2010 Nov; 67(11):1329-35. PubMed ID: 20625068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
    Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
    J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.